Previous close | 106.10 |
Open | 106.39 |
Bid | 107.42 x 1300 |
Ask | 107.50 x 800 |
Day's range | 106.05 - 107.72 |
52-week range | 78.66 - 113.41 |
Volume | 5,903,250 |
Avg. volume | 7,442,741 |
Market cap | 189.79B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | 39.54 |
EPS (TTM) | 2.72 |
Earnings date | 30 Apr 2021 |
Forward dividend & yield | 5.20 (4.84%) |
Ex-dividend date | 14 Apr 2021 |
1y target est | 122.17 |
AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) -- especially stand out due to their attractive valuations. Which is the better value stock? You might think that neither AbbVie nor Viatris qualifies as value stocks based on their trailing-12-month price-to-earnings (P/E) ratios.
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
The Zacks Analyst Blog Highlights: ServiceNow, AbbVie and Apple